Abcellera Biologics Inc is trading 12.6% up at $6.44 as traders position ahead of the company’s presentation at the Jefferies Global Healthcare Conference.
- Investors are speculating that the upcoming presentation could highlight significant pipeline and partnership updates to justify the company's approximately $1.8 billion valuation.
- The stock is seeing strong short-term momentum and speculative interest, building on a previous gain that brought shares up from $6.17.
- The rally occurs despite the company reporting only $8 million in revenue during the last quarter, as the market focuses on future growth potential.